Insulet Corp. (PODD)
147.48
-3.10
(-2.06%)
USD |
NASDAQ |
Sep 04, 16:00
147.43
-0.05
(-0.03%)
Pre-Market: 20:00
Insulet Research and Development Expense (Quarterly) : 88.10M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 88.10M |
| March 31, 2026 | 89.70M |
| December 31, 2025 | 90.90M |
| September 30, 2025 | 77.20M |
| June 30, 2025 | 73.40M |
| March 31, 2025 | 59.60M |
| December 31, 2024 | 60.60M |
| September 30, 2024 | 54.90M |
| June 30, 2024 | 53.90M |
| March 31, 2024 | 50.20M |
| December 31, 2023 | 42.00M |
| September 30, 2023 | 57.80M |
| June 30, 2023 | 55.10M |
| March 31, 2023 | 50.10M |
| December 31, 2022 | 49.50M |
| September 30, 2022 | 45.00M |
| June 30, 2022 | 42.60M |
| March 31, 2022 | 43.10M |
| December 31, 2021 | 41.80M |
| September 30, 2021 | 37.50M |
| June 30, 2021 | 40.10M |
| March 31, 2021 | 40.70M |
| December 31, 2020 | 38.30M |
| September 30, 2020 | 38.80M |
| June 30, 2020 | 34.20M |
| Date | Value |
|---|---|
| March 31, 2020 | 35.50M |
| December 31, 2019 | 34.70M |
| September 30, 2019 | 30.78M |
| June 30, 2019 | 32.26M |
| March 31, 2019 | 31.95M |
| December 31, 2018 | 28.51M |
| September 30, 2018 | 21.76M |
| June 30, 2018 | 18.42M |
| March 31, 2018 | 20.27M |
| December 31, 2017 | 18.78M |
| September 30, 2017 | 20.14M |
| June 30, 2017 | 18.03M |
| March 31, 2017 | 17.50M |
| December 31, 2016 | 16.03M |
| September 30, 2016 | 13.73M |
| June 30, 2016 | 12.95M |
| March 31, 2016 | 12.99M |
| December 31, 2015 | 12.90M |
| September 30, 2015 | 10.04M |
| June 30, 2015 | 12.07M |
| March 31, 2015 | 8.207M |
| December 31, 2014 | 7.286M |
| September 30, 2014 | 7.158M |
| June 30, 2014 | 6.677M |
| March 31, 2014 | 6.779M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| DexCom, Inc. | 153.00M |
| Abbott Laboratories | 892.00M |
| Boston Scientific Corp. | 554.00M |
| PROCEPT BioRobotics Corp. | 20.10M |
| Globus Medical, Inc. | 36.32M |